Study of the molecular basis of fibrotic pathology and the molecular mechanisms related to TGFβ and Hsp90 for their treatment in vitro and in vivo.
Study the effects of new pharmacological strategies based on biotechnology, CRISPR/Cas mutations or modified plasmids for their use as teragnostic particles in vitro and in vivo.
Study of antifibrotic therapy and telomeric protection against SARS-CoV2 infection.
Generation of new nano-transport systems to reach therapeutic targets. Generation of new diagnostic tools.
en
ES
